Tensegrity Pharma

Tensegrity Pharma Focuses on Innovative Drug Development. The company's core project is TSP - 101, which targets cancer-related cachexia, can block specific factor signals, inhibit cancer-related systemic inflammation, and improve the tumor microenvironment to exert anti-cancer effects. This drug was taken over from a preclinical project of Astellas Pharma Corporation that was terminated for strategic reasons and is being advanced to Phase I/II clinical trials to quickly obtain clinical proof of concept. Centered on the concept of "tensegrity," the company relies on the autonomous collaboration of a small, specialized team to revitalize strategically terminated drug candidates, address bottlenecks in new drug development, and activate the drug research and development ecosystem.